Skip to main content

Table 1 Baseline demographics and disease characteristics

From: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine

Variable

EVOLVE-1 and EVOLVE-2 (Episodic Migraine Trials)

REGAIN (Chronic Migraine Trial)

PBO

N = 894

GMB 120 mg

N = 444

GMB 240 mg N = 435

Total N = 1773

PBO

N = 558

GMB 120 mg

N = 278

GMB 240 mg

N = 277

Total N = 1113

Age, years, mean (SD)

41.5 (11.3)

40.6 (11.4)

40.1 (11.5)

41.0 (11.4)

41.6 (12.1)

39.7 (11.9)*

41.1 (12.4)

41.0 (12.1)

Female, n (%)

755 (84.5)

378 (85.1)

366 (84.1)

1499 (84.6)

483 (87)

237 (85)

226 (82)

946 (85.0)

Years since migraine diagnosis, mean (SD)

20.3 (12.3)

20.7 (12.1)

19.5 (11.9)

20.2 (12.2)

21.9 (12.9)

20.4 (12.7)

20.1 (12.7)*

21.1 (12.8)*

Number of migraine headache days/month

10.9 (2.0)

10.9 (2.0)

10.7 (2.0)

10.8 (2.0)

19.6 (4.6)

19.4 (4.3)

19.2 (4.6)

19.4 (4.5)

Number of severe migraine headache days/month

2.6 (2.4)

2.5 (2.3)

2.7 (2.3)

2.6 (2.3)

6.6 (5.2)

6.7 (4.9)

6.6 (4.8)

6.6 (5.0)

Number of moderate-severe migraine headache days

7.4 (3.0)

7.4 (3.0)

7.5 (3.1)

7.4 (3.1)

16.1 (5.4)

16.0 (5.2)

15.7 (5.4)

16.0 (5.4)

Mean severity of migraine headache daysa

2.1 (0.4)

2.1 (0.4)

2.1 (0.4)

2.1 (0.4)

2.2 (0.4)

2.2 (0.4)

2.2 (0.4)

2.2 (0.4)

Number of migraine headache days with aura

3.1 (3.8)

2.8 (3.4)

3.1 (3.6)

3.0 (3.7)

5.0 (6.9)

5.3 (7.3)

4.8 (7.0)

5.0 (7.0)

Number of migraine headache days with nausea and/or vomiting

4.6 (3.4)

4.7 (3.4)

4.8 (3.3)

4.7 (3.4)

9.2 (6.9)

8.8 (6.3)

8.1 (6.5)*

8.8 (6.7)

Number of migraine headache days with photophobia and phonophobia

8.4 (3.5)

8.1 (3.6)

8.1 (3.6)

8.3 (3.5)

15.2 (7.2)

14.8 (7.0)

14.0 (7.6)*

14.8 (7.3)

Number of migraine headache days with prodromal symptoms

3.9 (3.8)

3.8 (3.8)

3.7 (3.7)

3.9 (3.8)

6.8 (7.3)

7.3 (7.5)

7.1 (7.3)

7.0 (7.4)

Proportion of migraine headache days with nausea and vomiting

40.4 (30.1)

41.8 (32.0)

42.3 (30.2)

41.2 (30.6)

46.4 (31.3)

44.7 (29.3)

41.5 (30.3)

44.8 (30.6)

Proportion of migraine headache days with photophobia and phonophobia

74.5 (30.2)

72.8 (31.8)

73.9 (30.7)

73.9 (30.7)

76.4 (29.6)

75.0 (29.7)

71.6 (32.7)

74.8 (30.5)

  1. *p ≤ 0.05 vs. PBO; **p ≤ 0.01 vs. PBO. aSeverity ratings: 1 = mild, 2 = moderate, 3 = severe
  2. GMB Galcanezumab, PBO Placebo, SD Standard deviation